BioCentury | Aug 11, 2014
Strategy

Profusion of exclusions

Express Scripts Holding Co. 's 2015 formulary exclusions offer hope that companies can renegotiate once-excluded drugs back into coverage. But the pharmacy benefits manager appears to be expanding the number of drugs and drug classes...
BioCentury | Dec 16, 2013
Strategy

Out in the cold

New excluded drugs lists devised by pharmacy benefits managers are raising the hurdle for reimbursement of drugs the PBMs' pharmacy and therapeutics committees consider to be clinically equivalent to cheaper drugs. Drugs that are not...
BC Week In Review | Jul 15, 2013
Company News

Covidien neurology, autoimmune news

Covidien completed the spin-off of its pharmaceuticals business - its Mallinckrodt plc subsidiary - into a separate public company. Mallinckrodt began trading on the NYSE under the ticker "MNK" on July 1. Covidien shareholders received one Mallinckrodt...
BC Week In Review | Sep 3, 2012
Clinical News

Exalgo regulatory update

FDA approved an sNDA from Covidien's Mallinckrodt Inc. subsidiary for a 32 mg dose tablet of Exalgo hydromorphone to treat moderate to severe pain in opioid-tolerant patients. Zalicus said the 32 mg dose will be...
BC Week In Review | Feb 6, 2012
Company News

Watson, Covidien neurology news

Watson and Covidien's Mallinckrodt Inc. subsidiary settled a December 2010 suit filed in the U.S. District Court for the District of New Jersey claiming that Watson infringed U.S. Patent No. 5,914,131 covering pain drug Exalgo...
BC Week In Review | Dec 19, 2011
Company News

Covidien neurology news

Covidien plans to spin off its pharmaceuticals business into a separate public company that Covidien says will compete more effectively in the pain management area. The business accounted for $2 billion, or 17%, of Covidien's...
BC Extra | Dec 16, 2011
Company News

Covidien planning pharma spin-off

Covidien plc (NYSE:COV) plans to spin off its pharmaceuticals business into a separate public company that Covidien says will compete more effectively in the pain management area. The business accounted for $2 billion, or 17%,...
BioCentury | Jul 11, 2011
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 7/8 close Cepheid Inc. (NASDAQ:CPHD) Goldman Sachs Isaac Ro Downgrade Neutral (from buy) -8% $32.40 Ro downgraded based on Cepheid's strong stock performance. He...
BioCentury | Jul 4, 2011
Finance

3Q Financial Markets Preview: Hoping the rally has legs

Buysiders expect biotech may be able to continue to outperform the broader markets, despite a retreat from spring highs. In particular, they see two bright spots for the sector: selective gains on a full calendar...
BioCentury | Jan 10, 2011
Finance

Buyside View XIX: Commercial Risk

Michael Flanagan Senior Writer  BioCentury's 19th Annual Buyside View finds money managers entering 2011 cautiously optimistic about biotech's prospects, particularly as some of the high-profile compounds have already reported some data, lowering risk. Amidst the...
Items per page:
1 - 10 of 56